These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 22801507

  • 1. HO-3867, a STAT3 inhibitor induces apoptosis by inactivation of STAT3 activity in BRCA1-mutated ovarian cancer cells.
    Tierney BJ, McCann GA, Cohn DE, Eisenhauer E, Sudhakar M, Kuppusamy P, Hideg K, Selvendiran K.
    Cancer Biol Ther; 2012 Jul; 13(9):766-75. PubMed ID: 22801507
    [Abstract] [Full Text] [Related]

  • 2. HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition.
    Selvendiran K, Ahmed S, Dayton A, Kuppusamy ML, Rivera BK, Kálai T, Hideg K, Kuppusamy P.
    Cancer Biol Ther; 2011 Nov 01; 12(9):837-45. PubMed ID: 21885917
    [Abstract] [Full Text] [Related]

  • 3. Diarylidenylpiperidones, H-4073 and HO-3867, Induce G2/M Cell-Cycle Arrest, Apoptosis and Inhibit STAT3 Phosphorylation in Human Pancreatic Cancer Cells.
    Mast JM, Tse D, Shee K, Lakshmi Kuppusamy M, Kmiec MM, Kálai T, Kuppusamy P.
    Cell Biochem Biophys; 2019 Jun 01; 77(2):109-119. PubMed ID: 31089934
    [Abstract] [Full Text] [Related]

  • 4. Targeting STAT3 by HO3867 induces apoptosis in ovarian clear cell carcinoma.
    Bixel K, Saini U, Kumar Bid H, Fowler J, Riley M, Wanner R, Deepa Priya Dorayappan K, Rajendran S, Konishi I, Matsumura N, Cohn DE, Selvendiran K.
    Int J Cancer; 2017 Nov 01; 141(9):1856-1866. PubMed ID: 28646535
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Anticancer potential of diarylidenyl piperidone derivatives, HO-4200 and H-4318, in cisplatin resistant primary ovarian cancer.
    ElNaggar AC, Saini U, Naidu S, Wanner R, Sudhakar M, Fowler J, Nagane M, Kuppusamy P, Cohn DE, Selvendiran K.
    Cancer Biol Ther; 2016 Oct 02; 17(10):1107-1115. PubMed ID: 27415751
    [Abstract] [Full Text] [Related]

  • 9. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
    Pulliam N, Fang F, Ozes AR, Tang J, Adewuyi A, Keer H, Lyons J, Baylin SB, Matei D, Nakshatri H, Rassool FV, Miller KD, Nephew KP.
    Clin Cancer Res; 2018 Jul 01; 24(13):3163-3175. PubMed ID: 29615458
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Mild oxidative stress induces S-glutathionylation of STAT3 and enhances chemosensitivity of tumoural cells to chemotherapeutic drugs.
    Butturini E, Carcereri de Prati A, Chiavegato G, Rigo A, Cavalieri E, Darra E, Mariotto S.
    Free Radic Biol Med; 2013 Dec 01; 65():1322-1330. PubMed ID: 24095958
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. BRCA1-IRIS overexpression promotes cisplatin resistance in ovarian cancer cells.
    Chock KL, Allison JM, Shimizu Y, ElShamy WM.
    Cancer Res; 2010 Nov 01; 70(21):8782-91. PubMed ID: 20940403
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Active Hexose Correlated Compound (AHCC) Inhibits the Proliferation of Ovarian Cancer Cells by Suppressing Signal Transducer and Activator of Transcription 3 (STAT3) Activation.
    Choi JY, Lee S, Yun SM, Suh DH, Kim K, No JH, Jeong EH, Kim YB.
    Nutr Cancer; 2018 Jan 01; 70(1):109-115. PubMed ID: 29111786
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Safe and targeted anticancer efficacy of a novel class of antioxidant-conjugated difluorodiarylidenyl piperidones: differential cytotoxicity in healthy and cancer cells.
    Selvendiran K, Ahmed S, Dayton A, Kuppusamy ML, Tazi M, Bratasz A, Tong L, Rivera BK, Kálai T, Hideg K, Kuppusamy P.
    Free Radic Biol Med; 2010 May 01; 48(9):1228-35. PubMed ID: 20156552
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.